XOMA241220P20000
- 0.75
- 0.000.00%
XOMA Corp Newsroom
XOMA Royalty Corporation (NASDAQ:XOMA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Express News | XOMA Royalty Corp : Leerink Partners Raises Target Price to $55 From $49
TD Cowen Maintains XOMA Corp(XOMA.US) With Hold Rating
8-K: XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
10-Q: Q3 2024 Earnings Report
Earnings Flash (XOMA) XOMA CORPORATION Posts Q3 Revenue $7.2M
XOMA Royalty 3Q Rev $7.2M >XOMA
Express News | XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Express News | XOMA Q3 Net Income USD -17.2 Million
Press Release: XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
XOMA Royalty Down Nearly 11%, on Pace for Largest Percent Decrease Since January 2023 -- Data Talk
XOMA Royalty Significantly Expands Its Royalty and Milestone Portfolio With the Addition of Over 60 Early-Stage Programs From Twist Bioscience
While Shareholders of XOMA Royalty (NASDAQ:XOMA) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate
XOMA Corp - 8.375% DP PFD B Declares $0.5234 Dividend
Express News | XOMA Royalty Says Zevra Therapeutics Received FDA Approval For MIPLYFFA; Says It Is Entitled To Receive Mid-single Digit Royalty On MIPLYFFA Sales And Up To $52.6M In Milestones
Zevra's MIPLYFFA (Arimoclomol) Receives Approval From U.S. Food and Drug Administration for Use in Patients With Niemann-Pick Disease Type C (NPC)
Express News | Zevra’s Miplyffa™ (Arimoclomol) Receives Approval From U.S. Food and Drug Administration for Use in Patients With Niemann-Pick Disease Type C (Npc)
Press Release: XOMA Royalty Declares Quarterly Preferred Stock Dividends
H.C. Wainwright Maintains XOMA Corp(XOMA.US) With Buy Rating, Maintains Target Price $117
XOMA Royalty to Present at Upcoming Investor Conferences in September